Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

BACKGROUND: Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast cancer (MBC) patients. METHODS: A cohort of HER2-positive MBC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Binliang, Xie, Ning, Tian, Can, Feng, Ronghua, Hu, Zhe-Yu, Li, Jing, Liu, Liping, Xiao, Huawu, Yang, Xiaohong, Zeng, Mengsi, Wu, Hui, Lu, Jun, Gao, Jianxiang, Hu, Xuming, Cao, Min, Shui, Zhengrong, Tang, Yu, Wu, Tao, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654023/
https://www.ncbi.nlm.nih.gov/pubmed/37944341
http://dx.doi.org/10.1016/j.breast.2023.103597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654023/
https://www.ncbi.nlm.nih.gov/pubmed/37944341
http://dx.doi.org/10.1016/j.breast.2023.103597

Ejemplares similares